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Summary
We observed a novel therapeutic response with cabergoline in a male patient with a dopamine-secreting head and 
neck paraganglioma (HNPGL), macroprolactinoma and germline succinate dehydrogenase C mutation (SDHC). The 
macroprolactinoma was treated with cabergoline which gave an excellent response. He was found to have raised plasma 
3-methoxytyramine of 1014 pmol/L (NR: 0–180 pmol/L); but it was unclear if this was a drug-induced phenomenon 
from dopamine agonist (DA) therapy. Cabergoline was stopped for 4 weeks and the 3-methoxytyramine level increased 
significantlyto2185pmol/L,suggestingabiochemicalresponseofhisHNPGL.Subsequently,Gallium-68DotatatePETand
MRI(Gallium-68DotatatePET/MRI)demonstratedasecondlesioninthesacrum.BoththeHNPGLandmetastaticsacral
deposit received external beam radiotherapy with a good biochemical and radiological response. 
Conclusion: Our case report highlights the rare potential of germline SDHC mutations causing metastatic paraganglioma 
and concurrent pituitary tumours. Cabergoline treatment may lower elevated 3-methoxytyramine levels and, therefore, 




should be addressed 




 • Several neuroendocrine tumours (NETs) express dopamine D2 and D4 receptors. In this case report, cabergoline 
significantlyreducedplasma3-methoxytyraminelevelinapatientwithfunctionalHNPGL.Cabergolinemighthave
therapeutic relevance in dopamine-secreting PPGLs.
 • Paragangliomas associated with SDHC mutation classically present with asymptomatic non-functional HNPGL and 
have rare metastatic potential.
 • The association of pheochromocytoma or paraganglioma and pituitary adenoma is now a well-described rare 
association (<1%), designated as the three P association. While the three P association is most commonly seen 
with succinate dehydrogenase B and D mutations, it has also been described in patients with SDHA and SDHC 
mutations.
 • Cabergoline treatment may lower elevated 3-methoxytyramine levels and mask the biochemical evidence of 
metastaticdisease.RegularfunctionalimagingwithGallium-68DotatatePET/MRIprovidesbetterevidenceof
metastatic disease.
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Background
HNPGL are NETs, arising from parasympathetic ganglia 
in the neck and skull base. These tumours present mainly 
with non-specific symptoms, including painless neck 
masses compressing the cranial nerves or invading the 
skull base. It has been reported that up to one-third of 
HNPGL patients have biochemically active tumours 
producing 3-methoxytyramine (1), which is a metabolite 
of dopamine. The increased production of dopamine has 
been shown to be an independent marker for metastatic 
disease (2).
Several NETs exhibit dopamine D2 and D4 receptors, 
including pheochromocytoma (PCC) and paraganglioma 
(PGL) (3,4), suggesting that these tumours might be 
amenable to dopaminergic therapy.
In our case report, we present a possible therapeutic 
response in a patient with dopamine-secreting HNPGL 
and a pituitary adenoma associated with germline SDHC 
mutation. We observed a novel association of decreased 
plasma 3-methoxytyramine with cabergoline administered 
for pituitary macroprolactinoma. This case is also unique, 
it highlights the rare association of metastatic disease from 
HNPGL with pituitary adenoma and SDHC mutation.
Case presentation
A 64-year-old man presented in 1993 with swallowing 
difficulties caused by HNPGL. He underwent two trans-
temporal resections in 1993 and 2000; complete excision 
of the tumour was not possible due to its size and proximity 
to crucial neck structures. The residual disease remained 
stable and was monitored with regular MRI under the Ear, 
Nose and Throat surgeons. In 2008, a surveillance MRI 
demonstrated an incidental pituitary macroadenoma (Fig. 
1). Apart from occasional headaches, he had no history 
of hypertension, palpitations or sweating to suggest 
catecholamine overproduction. On examination in 2008, 
his blood pressure was 112/78 mmHg and pulse rate of 90 
b.p.m. He had normal visual fields, but residual right-sided 
7th, 9th, 10th, 11thand 12th cranial nerves deficits due to 
previous surgeries.
Investigations
His pituitary profile showed a markedly raised prolactin 
of 43 000 mIU/L (NR: 86–324 mIU/L). The patient was 
then referred to endocrinology and started on cabergoline 
0.5 mg weekly; the macroprolactinoma demonstrated 
an excellent response with normalisation of serum 
prolactin within 1 year. MRI scan in 2011 (Fig. 1) showed 
a significant reduction in prolactinoma size from baseline; 
the cabergoline dose was subsequently reduced to 0.25 mg 
weekly. 
Interestingly, his family history revealed a brother 
with a diagnosis of HNPGL and a maternal cousin with 
non-functioning pituitary adenoma (NFPA), both were 
in their fifties. Genetic testing found that our index case 
harboured a novel missense variant in SDHC gene c.380A>G 
(p.His127Arg) with a gnomAD minor allele frequency 
of 0.0000315. The same genetic alteration was found in 
his brother with paraganglioma. The proband’s mother, 
aunt, sister, two nephews and one niece are carriers of the 
same mutation but have no clinical manifestation to date 
while the cousin with NFPA had no SDHC gene alteration 
detected, he was considered to represent a phenocopy. No 
mutations were identified in multiple endocrine neoplasia 
1 gene (MEN 1) and Aryl hydrocarbon receptor interacting 
protein (AIP) gene in the proband or his family members. 
Family pedigree is shown in Fig. 2.
In May 2012, he complained of occasional headaches, 
but no other symptoms. His PGL showed radiological 
evidence of progression and compression of the right 
internal carotid artery. At this stage, the biochemical 
assessment of the PGL was performed for the first time. 
He had normal plasma metanephrine at 377 pmol/L (NR: 
80–510 pmol/L) and normetanephrine at 284 pmol/L 
(NR: 120–1180 pmol/L) but raised 3-methoxytyramine 
concentration at 1014 pmol/L (NR: 0–180 pmol/L). We 
questioned if the isolated rise in 3-methoxytyramine 
was a drug-induced phenomenon caused by DA. 
Cabergoline was temporarily stopped for 4 weeks; plasma 
Figure 1
(A) T1 weighted MRI of the head (coronal view) performed in 2008 showed 
an incidental pituitary macroadenoma (red arrow). (B) T1 weighted MRI of 
the head (coronal view) in 2011 showed the macroadenoma responded 
well to dopamine agonist therapy with a reduction in size.





3-methoxytyramine level increased substantially to 1965 
pmol/L and 2185 pmol/L at 2 and 4 weeks of ceasing the 
drug, respectively. After restarting cabergoline, plasma 
3-methoxytyramine dropped down and returned to the 
previously raised level (Fig. 3). Elevated 3-methoxytyramine 
was concerning as the metabolite is considered a marker for 
metastatic disease in PPGLs (2). Subsequently, functional 
imaging with Gallium-68 Dotatate PET/MRI demonstrated 
avid uptake at his residual neck disease and a small focus 
of uptake in the sacral body (S2) suggestive of metastatic 
focus (Fig. 4). To further characterise the lesion, an MRI of 
the sacrum with diffusion sequences showed a 7 × 12 mm 
lesion compatible with PGL deposit. A sacral biopsy was 
not attempted because of the small size and high risk of 
neural injury. 
Treatment
The patient continued on cabergoline 0.25 mg weekly 
and received 50.4 Gray of fractionated external beam 
radiotherapy to both skull base and the sacral lesions in 
December 2015. 
Outcome and follow-up
Five years post-irradiation, the patient remained stable. 
Plasma 3-methoxytyramine reduced to 489 pmol/L. 
Gallium-68 Dotatate PET/MRI scan in 2020 demonstrated 
stable disease at the skull base and sacrum. Prolactin 
remained within reference range on cabergoline 0.25 mg 
once weekly. MRI pituitary continued to show regressing 
pituitary adenoma with the plan to repeat surveillance 
scanning in 5 years. Annual measurement of plasma 
metanephrines and periodic radiological assessment (MRI/ 
Gallium-68 Dotatate PET/MRI) are in place to monitor 
PGL activity and progression of metastatic disease. His 
asymptomatic carrier family members are under regular 
screening follow-up with their local endocrinologists.
Discussion
Cabergoline is an ergot-derived dopamine 2 (D2) receptor 
agonist. Some studies have reported the expression of 
D2 receptors in various NETs including gastrointestinal, 
pancreatic and bronchial NETs and PCC (3,5). Saveanu 
 et al. (4) studied 52 patients with PPGLs including patients 
with SDHB and SDHD mutation, all tumours expressed 
high levels of D2 mRNA as surrogate evidence of D2 
receptors. Their data showed that D2 is expressed in PGL 
at high levels (though not as high as PCC). It has been 
shown that the activation of dopamine receptors inhibits 
endogenous dopamine release with the subsequent 
reduction of dopamine metabolism to its metabolites 
including 3-methoxytyramine (6). The evidence of 
antisecretory and possibly antiproliferative effect of DA 
has been seen in ACTH-secreting bronchial NETs (5) and 
metastatic islet cell tumours (7). However, the effect of D2 
receptor agonists remains uncertain in PPGLs but may have 
clinical relevance in treating dopamine secreting PPGLs. 
Exclusive dopamine-secreting PPGLs differ in 
the clinical presentation when compared with other 
catecholamine-producing counterparts. These tumours 
are typically associated with extra adrenal location 
and have more metastatic potential than other 
catecholamine-secreting tumours (2). This behaviour 
has been attributed to poor cellular differentiation and 
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This family pedigree chart demonstrates the family history of the index 
patient who is marked with an arrow. NFPA, non-functioning pituitary 
adenoma; PGL, paraganglioma.
Figure 3
Plasma 3-methoxytyramine concentrations with dopamine agonists and 
radiotherapy. 3-methoxytyramine concentrations doubled after stopping 
cabergoline and returned to raised earlier concentration after re-starting 
therapy. 3MT, 3-methoxytyramine; mg, milligram; wk, week.
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delayed clinical presentation due to the absence of 
symptoms. Elevated plasma 3-methoxytyramine can 
be considered as an independent marker of metastatic 
potential and can increase up to five-fold in patients with 
metastasis compared to those without (2). Our patient was 
normotensive and asymptomatic from dopamine excess; 
the effect of cabergoline on his 3-methoxytyramine is 
clearly demonstrated. It is unclear if the use of DAs had a 
definite effect on his tumour control/progression or likely 
response to radiotherapy. To date, no further metastasis 
has been detected. It would be of interest to explore the 
antiproliferative effects of DAs in dopamine-secreting 
PPGLs.
The association of PCC or PGL and pituitary adenoma 
is now a well-described rare (<1%) association, designated 
as the three P association or '3PA'. PGLs associated 
with SDHC mutation classically present with isolated 
asymptomatic, non-functional HNPGL. The first case of 
metastatic PGL with distant metastases caused by SDHC 
mutation was described in 2014 by Bickman   et  al. (8). 
Subsequently, others have also published metastatic 
PGL in SDHC (9,10). In our patient, the relationship of 
pituitary tumour and SDHC remains undefined, as loss of 
heterozygosity or a second somatic mutation study is not 
available as the macroprolactinoma was treated medically. 
Our case highlights the rare potential of germline 
SDHC mutations causing metastatic HNPGL with 
concurrent prolactin-secreting pituitary tumours and 
an interesting effect on 3-methoxytyramine with the 
use of DA. Cabergoline treatment may lower elevated 
3-methoxytyramine levels but equally, it could mask the 
biochemical evidence of metastasis. Therefore, Gallium-68 
Dotatate PET/MRI scanning provides better evidence of 
metastatic disease.
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Figure 4
(A and B) PET and MRI of the head and neck (A: 
coronal view, B: axial view) demonstrated avid 
uptake at the right-sided residual paraganglioma 
lesion (red arrows). (C and D) PET/MRI scan of 
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demonstrated avid uptake at the site of 
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(red arrows). (E) Imaging showed increased 
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showedincreasedGallium-68Dotatateinthe
sacral region (red arrow).
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